---
title: "Mind Medicine MindMed (MNMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MNMD.US.md"
symbol: "MNMD.US"
name: "Mind Medicine MindMed"
industry: "Pharmaceuticals"
datetime: "2026-05-21T14:40:23.654Z"
locales:
  - [en](https://longbridge.com/en/quote/MNMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MNMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MNMD.US.md)
---

# Mind Medicine MindMed (MNMD.US)

## Company Overview

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.80 | 180 | - | - | - |
| PB | 11.33 | 181 | 11.33 | 8.86 | 3.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-31T05:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 77% |
| Overweight | 3 | 23% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.02 |
| Highest Target | 61.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MNMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MNMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MNMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MNMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**